Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Pall ForteBio market leader of robust, label-free molecular interaction analysis across academic research, drug discovery and development, process analytics, and manufacturing.
Pall ForteBio a division of Pall Life Sciences is a globally operating high-tech company that develops, produces and markets analytical systems to accelerate biotherapeutic drug discovery and development. These advanced bio-analytical systems facilitate unique real-time, label-free insights into molecular interactions, providing information on affinity, kinetics and concentration. The company supports rapid and cost-effective decision making in life science research and development by measuring biomolecular interactions involving cells, antibodies, proteins, small molecules and fragments using high throughput label-free analytical instruments powered by BLI and SPR technology.
Target groups for the Company's products consist primarily of medical and life science research laboratories and pharmaceutical and biotechnology companies around the world. Pall ForteBio is focusing on drug discovery and development as its prime areas for future growth. The Company currently has nine systems on the market, the most important of which are: Octet RED96e, which offers flexibility in key life science research and drug discovery applications upstream of high-throughput screening (HTS), such as target identification and validation, and Octet HTX for applications downstream of HTS, including rapid characterization of HTS hits and comprehensive pre-clinical evaluation of lead compounds. BLItz is a manual instrument for verification of protein presence, concentration analysis of biopharmaceuticals and fast kinetic checks in only 4 μl of sample. Pioneer FE, a SPR based instrument which will provide higher information content in fragment screening was recently added to the company’s portfolio.
Pall ForteBio provides faster, more efficient and easier-to-use workflows which advance scientific findings across academic research, drug discovery and development, process analytics and manufacturing.
For more information, visit www.fortebio.com.